"Novo is a pharmaceutical stock with a key focus on treating diabetes. As the incidence of diabetes has risen in the U.S. and elsewhere, Novo's insulin and blood-sugar drugs have become market leaders.
That doesn't mean Novo has had a free ride, though. Amylin, which Bristol-Myers Squibb (NYSE: BMY ) bought this summer, got FDA approval for Bydureon, a drug that requires only weekly injections rather than the daily injections that Novo's Victoza requires. Moreover, MannKind (Nasdaq: MNKD ) is still fighting for approval on its inhaled insulin product Afreeza. If approved, Afreeza could do away with injections entirely for many diabetics, a Holy Grail in diabetes research that eluded giants Pfizer (NYSE: PFE ) and Eli Lilly (NYSE: LLY ) as well as Novo.
Lately, Novo has suffered from the European financial crisis, as investors have steered away from European stocks regardless of their particular exposure to the Continent. Novo gets less than 30% of its revenue from Europe, though, with North America and other international operations drawing the lion's share of its sales.
For Novo to improve, it needs to keep working on ways to cement its place within the diabetes and insulin spaces. Whether that means buying out potential competitors like MannKind or coming up with new developments on its own remains to be seen, but if it can succeed in either of those directions, it could go a long way toward helping the company get closer to perfection in the years ahead."
Eli Lilly will be positioned to be a superpower in the diabetes space if it's able to buy or partner with MNKD for AFREZZA. If it doesn#$%$ future will be in jeopardy.